Multiple outcomes of the germline p16
SASP
cellular senescence
familial melanoma syndrome
immunology
p16
skin
Journal
Aging cell
ISSN: 1474-9726
Titre abrégé: Aging Cell
Pays: England
ID NLM: 101130839
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
revised:
25
08
2024
received:
14
05
2024
accepted:
25
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
The integrated behaviour of multiple senescent cell types within a single human tissue leading to the development of malignancy is unclear. Patients with Familial Melanoma Syndrome (FMS) have heterozygous germline defects in the CDKN2A gene coding for the cyclin inhibitor p16
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14373Subventions
Organisme : Medical Research Council
ID : MR/T030534/1
Pays : United Kingdom
Organisme : Dermatrust
Organisme : LEO Fondet
ID : LF-OC-19-000192
Informations de copyright
© 2024 The Author(s). Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
Références
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011). Clearance of p16Ink4a‐positive senescent cells delays ageingassociated disorders. Nature, 479, 232–236.
Bishop, D. T., Demenais, F., Goldstein, A. M., Bergman, W., Bishop, J. N., Bressac‐de Paillerets, B., Chompret, A., Ghiorzo, P., Gruis, N., Hansson, J., Harland, M., Hayward, N., Holland, E. A., Mann, G. J., Mantelli, M., Nancarrow, D., Platz, A., & Tucker, M. A. (2002). Geographical variation in the penetrance of CDKN2A mutations for melanoma. Journal of the National Cancer Institute, 94, 894–903.
Blake, B. R., Kadin, J. A., Richardson, J. E., Smith, C. L., & Bult, C. J. (2021). Mouse Genome Database.
Bracken, O. V., De Maeyer, R. P. H., & Akbar, A. N. (in press 2024). Enhancing immunity during ageing by targeting interactions within the tissue environment. Nature Reviews Drug Discovery.
Brummel, K., Eerkens, A. L., de Bruyn, M., & Nijman, H. W. (2023). Tumour‐infiltrating lymphocytes: From prognosis to treatment selection. British Journal of Cancer, 128, 451–458.
Buj, R., Leon, K. E., Anguelov, M. A., & Aird, K. M. (2021). Suppression of p16 alleviates the senescence‐associated secretory phenotype. Aging (Albany NY), 13, 3290–3312.
Burton, D. G., & Krizhanovsky, V. (2014). Physiological and pathological consequences of cellular senescence. Cellular and Molecular Life Sciences, 71, 4373–4386.
Campisi, J. (2013). Aging, cellular senescence, and cancer. Annual Review of Physiology, 75, 685–705.
Castellano, M., Pollock, P. M., Walters, M. K., Sparrow, L. E., Down, L. M., Gabrielli, B. G., Parsons, P. G., & Hayward, N. K. (1997). CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Research, 57, 4868–4875.
Chambers, E. S., Vukmanovic‐Stejic, M., Shih, B., Trahair, T., Subramanian, P., Devine, O. P., Glanville, J., Gilroy, D. W., Rustin, M. H., Freeman, T. C., Mabbott, N. A., & Akbar, A. N. (2021). Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen‐specific tissue immunity during human aging. Nature Aging, 1, 101–113.
Chan, S. H., Chiang, J., & Ngeow, J. (2021). CDKN2A germline alterations and the relevance of genotype‐phenotype associations in cancer predisposition. Hered Cancer Clin Pract, 19, 21.
Che, H., Li, J., Li, Y., Ma, C., Liu, H., Qin, J., Dong, J., Zhang, Z., Xian, C. J., Miao, D., Wang, L., & Ren, Y. (2020). p16 deficiency attenuates intervertebral disc degeneration by adjusting oxidative stress and nucleus pulposus cell cycle. eLife, 9, e52570.
Coppé, J. P., Desprez, P. Y., Krtolica, A., & Campisi, J. (2010). The senescence‐associated secretory phenotype: The dark side of tumor suppression. Annual Review of Pathology, 5, 99–118.
Coppé, J. P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P. Y., & Campisi, J. (2008). Senescence‐associated secretory phenotypes reveal cell‐nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biology, 6, 2853–2868.
Denat, L., Kadekaro, A. L., Marrot, L., Leachman, S. A., & Abdel‐Malek, Z. A. (2014). Melanocytes as instigators and victims of oxidative stress. The Journal of Investigative Dermatology, 134, 1512–1518.
Elso, C. M., Roberts, L. J., Smyth, G. K., Thomson, R. J., Baldwin, T. M., Foote, S. J., & Handman, E. (2004). Leishmaniasis host response loci (lmr1‐3) modify disease severity through a Th1/Th2independent pathway. Genes and Immunity, 5, 93–100.
Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., Clark, W. H., Jr., & Tucker, M. A. (1995). Increased risk of pancreatic cancer in melanoma‐prone kindreds with p16INK4 mutations. The New England Journal of Medicine, 333, 970–974.
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., Gil, J., Hara, E., Krizhanovsky, V., Jurk, D., Maier, A. B., Narita, M., Niedernhofer, L., Passos, J. F., Robbins, P. D., … Demaria, M. (2019). Cellular senescence: Defining a path forward. Cell, 179, 813–827.
Harland, M., Cust, A. E., Badenas, C., Chang, Y. M., Holland, E. A., Aguilera, P., Aitken, J. F., Armstrong, B. K., Barrett, J. H., Carrera, C., Chan, M., Gascoyne, J., Giles, G. G., Agha‐Hamilton, C., Hopper, J. L., Jenkins, M. A., Kanetsky, P. A., Kefford, R. F., Kolm, I., … Puig, S. (2014). Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hereditary Cancer in Clinical Practice, 12, 20.
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009). Chemokine expression in melanoma metastases associated with CD8+ T‐cell recruitment. Cancer Research, 69, 3077–3085.
Hayflick, L. (1965). The limited in vitro lifetime of human diploid cell strains. Experimental Cell Research, 37, 614–636. https://clinvarminer.genetics.utah.edu.
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013). p53‐dependent chemokine production by senescent tumor cells supports NKG2Ddependent tumor elimination by natural killer cells. Journal of Experimental Medicine, 210, 2057–2069.
Iske, J., Roesel, M. J., Martin, F., Schroeter, A., Matsunaga, T., Maenosono, R., Tripathi, U., Xiao, Y., Nian, Y., Caldarone, B. J., Vondran, F. W. R., Sage, P. T., Azuma, H., Abdi, R., Elkhal, A., Pirtskhalava, T., Tchkonia, T., Kirkland, J. L., Zhou, H., & Tullius, S. G. (2024). Transplanting old organs promotes senescence in young recipients. American Journal of Transplantation, 24, 391–405.
Ivanov, A., Pawlikowski, J., Manoharan, I., van Tuyn, J., Nelson, D. M., Rai, T. S., Shah, P. P., Hewitt, G., Korolchuk, V. I., Passos, J. F., Wu, H., Berger, S. L., & Adams, P. D. (2013). Lysosome‐mediated processing of chromatin in senescence. The Journal of Cell Biology, 202, 129–143.
Kale, A., Sharma, A., Stolzing, A., Desprez, P.‐Y., & Campisi, J. (2020). Role of immune cells in the removal of deleterious senescent cells. Immunity & Ageing, 17, 16.
Kang, T.‐W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., Iken, M., Vucur, M., Weiss, S., Heikenwalder, M., Khan, S., Gil, J., Bruder, D., Manns, M., Schirmacher, P., … Zender, L. (2011). Senescence surveillance of pre‐malignant hepatocytes limits liver cancer development. Nature, 479, 547–551.
Krishnamurthy, J., Ramsey, M. R., Ligon, K. L., Torrice, C., Koh, A., Bonner‐Weir, S., & Sharpless, N. E. (2006). p16INK4a induces an age‐dependent decline in islet regenerative potential. Nature, 443, 453–457.
Kumari, R., & Jat, P. (2021). Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype. Frontiers in Cell and Development Biology, 9, 645593.
Laphanuwat, P., Gomes, D. C. O., & Akbar, A. N. (2023). Senescent T cells: Beneficial and detrimental roles. Immunological Reviews, 316, 160–175.
Lynch, H. T., Brand, R. E., Hogg, D., Deters, C. A., Fusaro, R. M., Lynch, J. F., Liu, L., Knezetic, J., Lassam, N. J., Goggins, M., & Kern, S. (2002). Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma‐pancreatic carcinoma‐prone families: The familial atypical mole melanoma‐pancreatic carcinoma syndrome. Cancer, 94, 84–96.
Mahnke, Y. D., Devevre, E., Baumgaertner, P., Matter, M., Rufer, N., Romero, P., & Speiser, D. E. (2012). Human melanoma‐specific CD8(+) T‐cells from metastases are capable of antigen‐specific degranulation and cytolysis directly ex vivo. Oncoimmunology, 1, 467–530.
McKenzie, H. A., Fung, C., Becker, T. M., Irvine, M., Mann, G. J., Kefford, R. F., & Rizos, H. (2010). Predicting functional significance of cancer‐associated p16(INK4a) mutations in CDKN2A. Human Mutation, 31, 692–701.
Mize, D., Bishop, M., Resse, E., et al. (2009). Familial atypical multiple mole melanoma syndrome. In Cancer Syndromes. National Center for Biotechnology Information (US).
Mukherji, B. (2013). Immunology of melanoma. Clinics in Dermatology, 31, 156–165.
Muul, L. M., Spiess, P. J., Director, E. P., & Rosenberg, S. A. (1987). Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. The Journal of Immunology, 138, 989–995.
Pereira, B. I., Devine, O. P., Vukmanovic‐Stejic, M., Chambers, E. S., Subramanian, P., Patel, N., Virasami, A., Sebire, N. J., Kinsler, V., Valdovinos, A., LeSaux, C. J., Passos, J. F., Antoniou, A., Rustin, M. H. A., Campisi, J., & Akbar, A. N. (2019). Senescent cells evade immune clearance via HLA‐E‐mediated NK and CD8(+) T cell inhibition. Nature Communications, 10, 2387.
Plunkett, F. J., Franzese, O., Belaramani, L. L., Fletcher, J. M., Gilmour, K. C., Sharifi, R., Khan, N., Hislop, A. D., Cara, A., Salmon, M., Gaspar, H. B., Rustin, M. H., Webster, D., & Akbar, A. N. (2005). The impact of telomere erosion on memory CD8+ T cells in patients with X‐linked lymphoproliferative syndrome. Mechanisms of Ageing and Development, 126, 855–865.
Potrony, M., Badenas, C., Aguilera, P., Puig‐Butille, J. A., Carrera, C., Malvehy, J., & Puig, S. (2015). Update in genetic susceptibility in melanoma. Annals of Translational Medicine, 3, 210.
R Core Team. (2022). R: A language and environment for statistical computing. https://www.Rproject.org/.
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter‐Kochanek, K., Jansen‐Dürr, P., & Wlaschek, M. (2006). p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell, 5, 379–389.
Rossi, M., Pellegrini, C., Cardelli, L., Ciciarelli, V., Di Nardo, L., & Fargnoli, M. C. (2019). Familial melanoma: Diagnostic and management implications. Dermatology Practical & Conceptual, 9, 10–16.
Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1997). Tumor‐suppressive pathways in pancreatic Carcinoma1. Cancer Research, 57, 1731–1734.
Sagiv, A., & Krizhanovsky, V. (2013). Immunosurveillance of senescent cells: The bright side of the senescence program. Biogerontology, 14, 617–628.
Salminen, A., Ojala, J., Kaarniranta, K., Haapasalo, A., Hiltunen, M., & Soininen, H. (2011). Astrocytes in the aging brain express characteristics of senescence‐associated secretory phenotype. The European Journal of Neuroscience, 34, 3–11.
Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte‐Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., & Herman, J. G. (1997). Abrogation of the Rb/p16 tumor‐suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57, 3126–3130.
Serra, S., & Chetty, R. (2018). p16. Journal of Clinical Pathology, 71, 853–858.
Serrano, M. (1997). The tumor suppressor protein p16INK4a. Experimental Cell Research, 237, 7–13.
Sviderskaya, E. V., Gray‐Schopfer, V. C., Hill, S. P., Smit, N. P., Evans‐Whipp, T. J., Bond, J., Hill, L., Bataille, V., Peters, G., Kipling, D., Wynford‐Thomas, D., & Bennett, D. C. (2003). p16/cyclindependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: Possible implications for melanoma progression. Journal of the National Cancer Institute, 95, 723–732.
Sviderskaya, E. V., Hill, S. P., Evans‐Whipp, T. J., Chin, L., Orlow, S. J., Easty, D. J., Cheong, S. C., Beach, D., DePinho, R. A., & Bennett, D. C. (2002). p16(Ink4a) in melanocyte senescence and differentiation. Journal of the National Cancer Institute, 94, 446–454.
Tuttle, C. S. L., Waaijer, M. E. C., Slee‐Valentijn, M. S., Stijnen, T., Westendorp, R., & Maier, A. B. (2020). Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis. Aging Cell, 19, e13083.
Victorelli, S., Lagnado, A., Halim, J., Moore, W., Talbot, D., Barrett, K., Chapman, J., Birch, J., Ogrodnik, M., Meves, A., Pawlikowski, J. S., Jurk, D., Adams, P. D., van Heemst, D., Beekman, M., Slagboom, P. E., Gunn, D. A., & Passos, J. F. (2019). Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. The EMBO Journal, 38, e101982.
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon‐Cardo, C., & Lowe, S. W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656–660.